CRESCENT BIOPHARMA, INC. 8K

Crescent Biopharma reported Q2 2026 results, outlined progress and timelines across its CR-001/CR-002/CR-003 oncology programs, and closed a $143.7 million public offering extending its cash runway into the second half of 2028.

On July 30, 2026, Crescent Biopharma, Inc. reported its financial results for the quarter ended June 30, 2026 and provided an update on its oncology pipeline and recent financing activities, highlighting continued enrollment in the global ASCEND Phase 1/2 trial of lead bispecific antibody CR-001, ongoing and newly initiated trials in China under its collaboration with Kelun-Biotech (including a Phase 2 CR-001 plus sacituzumab tirumotecan study in NSCLC and a Phase 1/2 CR-003 trial), plans to initiate a global Phase 1/2 trial of PD-L1–targeted ADC CR-002 in the second half of 2026, and expectations for multiple proof-of-concept and combination data readouts beginning in 2027, while also disclosing completion of a $143.7 million public offering that increases pro forma cash to $305.1 million as of June 30, 2026 and is expected to fund operations into the second half of 2028 despite a quarterly net loss of $24.8 million.

Filing Facts

CIK

1253689

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-050805

Alert Tier

6